Bellicum pharmaceuticals to participate in the h.c. wainwright 24th annual global investment conference

Houston, sept. 01, 2022 (globe newswire) -- bellicum pharmaceuticals, inc. (nasdaq: blcm), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that rick fair, president and ceo, will participate in the h.c. wainwright 24th annual global investment conference (hybrid). a pre-recorded presentation will be available to view on-demand beginning at 7 a.m. et / 4 a.m. pt on september 12, 2022, and will remain accessible for 90 days in the events and presentations section of the bellicum website.
BLCM Ratings Summary
BLCM Quant Ranking